Small cell carcinoma of the lung

David H. Johnson, F. Anthony Greco, Lawrence Einhorn

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Small cell lung cancer is a common neoplasm with unique biological and clinical features. It is more sensitive to both chemotherapy and radiation therapy than the other types of lung cancer which are collectively referred to as the "nonsmall cell lung cancers". By the late 1960s, it had become evident that local modalities of therapy, such as irradiation and surgical resection, were incapable of affecting long-term survival due to the proclivity of this neoplasm for early, widespread dissemination. Consequently, over the past 15 years, combination chemotherapy has become the cornerstone of management. However, the majority of patients with small cell lung cancer continue to die of their disease; thus, studies designed to improve treatment results and understand the basic biology of this cancer continue. Recently evaluated treatment strategies have included the use of "noncross resistant" chemotherapy, dose intensification, combined modality treatment employing locoregional irradiation in conjunction with chemotherapy, and "adjuvant" surgery. Several groups have also attempted to determine the optimum duration of chemotherapy, while others have focused on developing effective salvage therapy. Other investigators have concentrated on better understanding the basic biology of small cell lung cancers in an effort to develop potentially new therapeutic strategies to be used alone or in conjunction with current treatment modalities. Finally, our ability to prognosticate for small cell lung cancer is rather crude and efforts are underway to improve staging techniques. This article will review many of the studies of the past 5 years which have dealt with these issues.

Original languageEnglish
Pages (from-to)303-336
Number of pages34
JournalCritical Reviews in Oncology/Hematology
Volume4
Issue number4
DOIs
StatePublished - 1986

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Therapeutics
Salvage Therapy
Neoplasms
Adjuvant Chemotherapy
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Radiotherapy
Research Personnel
Survival

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Small cell carcinoma of the lung. / Johnson, David H.; Greco, F. Anthony; Einhorn, Lawrence.

In: Critical Reviews in Oncology/Hematology, Vol. 4, No. 4, 1986, p. 303-336.

Research output: Contribution to journalArticle

Johnson, David H. ; Greco, F. Anthony ; Einhorn, Lawrence. / Small cell carcinoma of the lung. In: Critical Reviews in Oncology/Hematology. 1986 ; Vol. 4, No. 4. pp. 303-336.
@article{530a37e53a4841d58ae21cfac8f98303,
title = "Small cell carcinoma of the lung",
abstract = "Small cell lung cancer is a common neoplasm with unique biological and clinical features. It is more sensitive to both chemotherapy and radiation therapy than the other types of lung cancer which are collectively referred to as the {"}nonsmall cell lung cancers{"}. By the late 1960s, it had become evident that local modalities of therapy, such as irradiation and surgical resection, were incapable of affecting long-term survival due to the proclivity of this neoplasm for early, widespread dissemination. Consequently, over the past 15 years, combination chemotherapy has become the cornerstone of management. However, the majority of patients with small cell lung cancer continue to die of their disease; thus, studies designed to improve treatment results and understand the basic biology of this cancer continue. Recently evaluated treatment strategies have included the use of {"}noncross resistant{"} chemotherapy, dose intensification, combined modality treatment employing locoregional irradiation in conjunction with chemotherapy, and {"}adjuvant{"} surgery. Several groups have also attempted to determine the optimum duration of chemotherapy, while others have focused on developing effective salvage therapy. Other investigators have concentrated on better understanding the basic biology of small cell lung cancers in an effort to develop potentially new therapeutic strategies to be used alone or in conjunction with current treatment modalities. Finally, our ability to prognosticate for small cell lung cancer is rather crude and efforts are underway to improve staging techniques. This article will review many of the studies of the past 5 years which have dealt with these issues.",
author = "Johnson, {David H.} and Greco, {F. Anthony} and Lawrence Einhorn",
year = "1986",
doi = "10.1016/S1040-8428(86)80026-9",
language = "English",
volume = "4",
pages = "303--336",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Small cell carcinoma of the lung

AU - Johnson, David H.

AU - Greco, F. Anthony

AU - Einhorn, Lawrence

PY - 1986

Y1 - 1986

N2 - Small cell lung cancer is a common neoplasm with unique biological and clinical features. It is more sensitive to both chemotherapy and radiation therapy than the other types of lung cancer which are collectively referred to as the "nonsmall cell lung cancers". By the late 1960s, it had become evident that local modalities of therapy, such as irradiation and surgical resection, were incapable of affecting long-term survival due to the proclivity of this neoplasm for early, widespread dissemination. Consequently, over the past 15 years, combination chemotherapy has become the cornerstone of management. However, the majority of patients with small cell lung cancer continue to die of their disease; thus, studies designed to improve treatment results and understand the basic biology of this cancer continue. Recently evaluated treatment strategies have included the use of "noncross resistant" chemotherapy, dose intensification, combined modality treatment employing locoregional irradiation in conjunction with chemotherapy, and "adjuvant" surgery. Several groups have also attempted to determine the optimum duration of chemotherapy, while others have focused on developing effective salvage therapy. Other investigators have concentrated on better understanding the basic biology of small cell lung cancers in an effort to develop potentially new therapeutic strategies to be used alone or in conjunction with current treatment modalities. Finally, our ability to prognosticate for small cell lung cancer is rather crude and efforts are underway to improve staging techniques. This article will review many of the studies of the past 5 years which have dealt with these issues.

AB - Small cell lung cancer is a common neoplasm with unique biological and clinical features. It is more sensitive to both chemotherapy and radiation therapy than the other types of lung cancer which are collectively referred to as the "nonsmall cell lung cancers". By the late 1960s, it had become evident that local modalities of therapy, such as irradiation and surgical resection, were incapable of affecting long-term survival due to the proclivity of this neoplasm for early, widespread dissemination. Consequently, over the past 15 years, combination chemotherapy has become the cornerstone of management. However, the majority of patients with small cell lung cancer continue to die of their disease; thus, studies designed to improve treatment results and understand the basic biology of this cancer continue. Recently evaluated treatment strategies have included the use of "noncross resistant" chemotherapy, dose intensification, combined modality treatment employing locoregional irradiation in conjunction with chemotherapy, and "adjuvant" surgery. Several groups have also attempted to determine the optimum duration of chemotherapy, while others have focused on developing effective salvage therapy. Other investigators have concentrated on better understanding the basic biology of small cell lung cancers in an effort to develop potentially new therapeutic strategies to be used alone or in conjunction with current treatment modalities. Finally, our ability to prognosticate for small cell lung cancer is rather crude and efforts are underway to improve staging techniques. This article will review many of the studies of the past 5 years which have dealt with these issues.

UR - http://www.scopus.com/inward/record.url?scp=0022365997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022365997&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(86)80026-9

DO - 10.1016/S1040-8428(86)80026-9

M3 - Article

C2 - 3006940

AN - SCOPUS:0022365997

VL - 4

SP - 303

EP - 336

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 4

ER -